This concurrent resolution directs the President to remove U.S. Armed Forces from hostilities against Iran unless explicitly authorized by a declaration of war or a congressional authorization for use of military force against Iran. Elements of the U.S. Armed Forces needed to defend the United States, an ally, or a partner from imminent attack are not covered by this requirement provided the President complies with a specified provision of the War Powers Resolution. (The provision generally requires the President to remove U.S. Armed Forces from hostilities no more than 60 days after the President notifies or is required to notify Congress of such involvement, unless Congress authorizes such use. For more information on the War Powers Resolution, see  CRS In Focus 13134 .)

Resolution· HCONRESH.Con.Res. 89 (119th)referred

Directing the President, pursuant to section 5(c) of the War Powers Resolution, to remove United States Armed Forces from hostilities with Iran.

United States · United States Congress · 23 April 2026

This concurrent resolution directs the President to remove U.S. Armed Forces from hostilities against Iran or any part of its government or military unless a declaration of war or authorization to use military force for such purpose has been enacted. The resolution specifies that it shall not be construed to prevent the United States from defending itself, its Armed Forces, its diplomatic facilities, or allied states from imminent attack.

Bill· HRH.R. 8327 (119th)referred

Communications, Video, and Technology Accessibility Act of 2026

United States · United States Congress · 16 April 2026

Bill· HRH.R. 8205 (119th)open

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

United States · United States Congress · 6 April 2026

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.  Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs. Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.

Bill· HRH.R. 8143 (119th)referred

Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026.

United States · United States Congress · 27 March 2026

Showing the 24 most recent records of 1,016. Browse the full list